Cardiff Oncology, Inc
Price
FilingsNewest: 8-K, Material agreementSep 14 →Insiders2 insiders bought $1.1M in 4 open-market buys. No sales.→HoldersLaurion 4.5%Vanguard 4.2%Pfizer 3.5%→Financing →PeersClosest companies: CRVS, NXTC, TNGX→
From the filings
Figures
- Revenue
- $508,000last 12 months
- Net income
- −$40.1Mlast 12 months
- Operating cash flow
- −$37.4Mlast 12 months
- Cash and equivalents
- $9.2Mat the last balance sheet
- Shares outstanding
- 68.5M shareson issue